Infectious Disease Deal Benchmarks
Benchmark deal terms across vaccines, HIV, hepatitis B functional cure programs, RSV prevention, and next-generation antibiotics. Post-pandemic platforms continue driving partnership activity. Benchmarks derived from 155 verified transactions.
155
Total Deals
$298M
Avg Upfront
7
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
72
license
29
acquisition
44
collaboration
3
option
5
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Aligos Therapeutics → Xiamen Amoytop Biotech Co., Ltd. pevifoscorvir sodium | license | $25M | $445M | Jul 2026 |
Memo Therapeutics AG → Ipsen potravitug | acquisition | $224M | $784M | Jul 2026 |
Aligos Therapeutics, Inc. → Xiamen Amoytop Biotech Co., Ltd. pevifoscorvir sodium | license | $25M | $445M | Apr 2026 |
Novavax → Pfizer Matrix-M | license | $30M | $530M | Apr 2026 |
GSK → Arrowhead JNJ-3989 | license | $1.0B | — | Apr 2026 |
Bluejay Therapeutics → Mirum Pharmaceuticals phase 3 hepatitis B/D drug | acquisition | $620M | $820M | Mar 2026 |
Bavarian Nordic → Nuance Pharma MVA-BN RSV vaccine | license | $13M | $225M | Mar 2026 |
Genevant/Arbutus → Moderna LNP patent license (settlement) | license | $950M | $2.3B | Mar 2026 |
Assembly Biosciences → Gilead Sciences ABI-5366 + ABI-1179 (HSV) | license | $35M | $365M | Dec 2025 |
CEPI → Moderna mRNA-1018 | collaboration | $54M | $54M | Dec 2025 |
Benchmark Your Infectious Disease Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 155 verified infectious disease transactions.
Infectious Disease Deal Benchmarking FAQ
How did COVID reshape infectious disease deal structures?
The pandemic permanently changed infectious disease deal-making by validating mRNA and viral vector platforms. Post-COVID deals increasingly feature platform licensing (not just single products), with licensees securing access to technology for multiple pathogens. Upfronts for platform deals range $100M-$500M+, significantly above pre-pandemic levels.
What are current HBV functional cure deal terms?
Hepatitis B functional cure programs are one of the most active segments, with multiple mechanisms (siRNA, ASO, capsid inhibitors, immunotherapy) being licensed. Combination approach deals are common, with upfronts of $50M-$200M and total deal values exceeding $1B for programs targeting the estimated 300M chronic HBV patients worldwide.
How do antibiotic deal structures address the commercial challenge?
Antibiotic deals are uniquely structured to address the "broken economics" of antimicrobials. Pull incentives (subscription models, guaranteed revenue floors) are increasingly incorporated into deal terms. Upfronts are typically lower ($10M-$50M) but include novel milestone structures tied to regulatory designations (QIDP, GAIN Act) rather than traditional sales thresholds.